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c-MYC is a radiosensitive locus in human breast cells
MA Wade1, NJ Sunter1, SE Fordham1, A Long1, D Masic1, LJ Russell1, CJ Harrison1, V Rand1, C Elstob1, N Bown2, D Rowe2, C Lowe2,
G Cuthbert2, S Bennett2, S Crosier1, CM Bacon1, K Onel3, K Scott4, D Scott5, LB Travis6, FEB May1 and JM Allan1
Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at
increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is
dose-dependent. Although it is well understood which individuals are at risk of radiation-induced breast carcinogenesis, the
molecular genetic mechanisms that underlie cell transformation are less clear. To identify genetic alterations potentially responsible
for driving radiogenic breast transformation, we exposed the human breast epithelial cell line MCF-10A to fractionated doses of
X-rays and examined the copy number and cytogenetic alterations. We identiﬁed numerous alterations of c-MYC that included
high-level focal ampliﬁcation associated with increased protein expression. c-MYC ampliﬁcation was also observed in primary
human mammary epithelial cells following exposure to radiation. We also demonstrate that the frequency and magnitude of c-MYC
ampliﬁcation and c-MYC protein expression is signiﬁcantly higher in breast cancer with antecedent radiation exposure compared
with breast cancer without a radiation aetiology. Our data also demonstrate extensive intratumor heterogeneity with respect to
c-MYC copy number in radiogenic breast cancer, suggesting continuous evolution at this locus during disease development and
progression. Taken together, these data identify c-MYC as a radiosensitive locus, implicating this oncogenic transcription factor in
the aetiology of radiogenic breast cancer.
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INTRODUCTION
Ionising radiation is a potent human carcinogen. Several tissues
and organs are susceptible to the transforming effects of ionising
radiation, including the breast in adolescent and young women in
whom risk is both dose- and age-dependent.1 In women treated
with radiotherapy for Hodgkin lymphoma, there is a linear
relationship between radiation exposure and breast cancer risk,
with those under the age of 20 years at the time of exposure at
the highest risk of developing subsequent breast cancer.2
Similarly, young women exposed to radiation after the atomic
bombs of Hiroshima and Nagasaki3–5 and those exposed to high
levels of diagnostic radiation6–9 have an elevated risk of breast
cancer.
The molecular genetic mechanisms that lead to radiogenic
breast cancer are unclear, but there is evidence that cancers
subsequent to radiation exposure have genotypic and phenotypic
features that distinguish them from other breast cancers, and
are more likely to be of the HER2 or basal-like subtypes.10
Furthermore, array comparative genomic hybridisation and
expression microarray analyses demonstrate that radiogenic
breast cancers cluster separately from other breast cancers10,11
and have a higher degree of genetic instability, such as a higher
frequency of allelic loss of chromosome bands 6q13–q14 and
9p21.12,13 Speciﬁc alterations have been implicated in radiogenic
breast transformation,14–18 but there is no evidence that any of
these genetic changes are induced directly by radiation exposure.
Understanding the pathogenesis and underlying molecular
genetic alterations that drive radiogenic breast cancer could
facilitate early detection in those who have been exposed to high
levels of ionising radiation and help tailor subsequent therapy. To
this end, we have used human cell model systems to identify
cytogenetic and copy number alterations induced by in vitro
exposure to ionising radiation, and determined the frequency of
these alterations in breast cancer patients with and without
antecedent radiation exposure.
RESULTS
Acquired copy number alterations in irradiated MCF-10A breast
epithelial cells
MCF-10A cells were irradiated with fractionated doses of X-rays to
a cumulative dose of 80 Gy using four independent dosing
regimens (two using 5 Gy and two using 10 Gy fractions), and copy
number alterations in irradiated cells were assessed by high-
density single-nucleotide polymorphism (SNP) array analysis
(Affymetrix SNP6.0, Affymetrix, La Jolla, CA, USA) by comparison
with parental MCF-10A. A number of large-scale and focal copy
number alterations were identiﬁed (Supplementary Tables 1–3),
including a 2.5 Mb focal copy number gain affecting the c-MYC
proto-oncogene on 8q in one of the 5 Gy dosing regimens
(Supplementary Table 1). Given the established role of c-MYC in
breast cancer pathogenesis, the aetiology and evolution of this
alteration was investigated in cells that had received a cumulative
radiation dose of 20, 40, 60 and 80 Gy. Comparison with parental
MCF-10A indicated no discernible copy number alterations in cells
that had received a cumulative dose of 20 Gy. However, in the
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40 Gy cumulative dose population, the 2.5 Mb copy number gain
of 8q, which includes the c-MYC, PVT1 and TMEM75 genes, ﬁrst
became discernible (Figure 1a and Supplementary Table 1). This
gain occurred within a 46 Mb region of chromosome 8q with an
inherent copy number of 3 in parental MCF-10A.19
In the 60Gy cumulative dose population, a further copy number
gain of ~ 59 Mb was apparent for chromosome 8q, which included
and extended beyond the 46 Mb region of copy number gain
present in parental MCF-10A (Figure 1a and Supplementary
Table 1). The telomeric breakpoint of the ~ 59 Mb gain was
unclear, but appeared to be located within the focal 2.5 Mb copy
number gain encompassing c-MYC. The array proﬁle of the 80 Gy
cumulative dose population was broadly similar to that observed
in the 60Gy population, although the large ~ 59 Mb copy number
gain and the focal 2.5 Mb copy number gain encompassing c-MYC
were more prominent features.
To further deﬁne the breakpoints in the proximity of the c-MYC
locus, we isolated 15 independent cell clones from the 80 Gy
population via limiting dilution and analysed these using very
high-density SNP arrays (Affymetrix Cytoscan). These data
identiﬁed two major sub-populations with distinct breakpoints
in the proximity of the c-MYC locus (Figure 1b). All 15 clones
carried the 2.5 Mb focal copy number gain affecting the c-MYC
locus ﬁrst identiﬁed in the 40 Gy population. Twelve of the
15 clones carried the additional ~ 59 Mb copy number gain
discernible from SNP6.0 data. Furthermore, these additional high-
density SNP data demonstrated that the telomeric breakpoint was
located within PVT1 (Supplementary Figure 1). This major clone
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Figure 1. SNP6.0 and Cytoscan array copy number proﬁle of chromosome 8 in parental and irradiated MCF-10A cell populations. Parental
MCF-10A and MCF-10A cells irradiated with fractionated X-ray doses of 5 Gy to a cumulative dose of 40, 60 and 80 Gy were assessed by SNP6.0
array (a). Each SNP marker on chromosome 8 is represented and aligned to its position on chromosome 8 as well as its designated copy
number state. An ideogram of chromosome 8 is positioned below the SNP marker plots. A 2.5 Mb copy number gain was identiﬁed in the
40 Gγ population and spans the c-MYC locus, increasing its copy number state from 3 to 4. The position of c-MYC is highlighted on each SNP
marker plot and the chromosome 8 ideogram by a red arrow. An ~ 59Mb copy number gain was identiﬁed in the 60 Gγ population, which
spanned a number of regions with different constitutive copy number states and also encompassed the c-MYC locus, therefore increasing its
copy number state further. The ~ 59Mb copy number gain ﬁrst identiﬁed in the 60 Gy population was further pronounced in the 80 Gy
population. The ~ 59Mb region is indicated by the horizontal black line above the SNP marker plots of the 60 and 80 Gy population. Clones
from MCF-10A cells irradiated with fractionated X-ray doses of 5 Gy to a cumulative dose of 80 Gy were assessed by Cytoscan array (b). All 15
clones analysed carried the focal 2.5Mb ampliﬁcation encompassing c-MYC. Twelve of the 15 clones carried the additional ~ 59Mb copy
number gain discernible from SNP6.0 data and a deletion affecting the p-arm of chromosome 8. Three of the 15 clones did not carry the
59Mb copy number gain or the p-arm deletion, but carried a novel copy number gain also encompassing the c-MYC gene.
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also carried a deletion affecting the p-arm of chromosome 8
(telomere-13 726 906). Three of the 15 clones did not carry the
~ 59 Mb copy number gain or the p-arm deletion described above.
Rather, these clones carried a novel copy number gain also
encompassing c-MYC (75 234 254– telomere), which was not
discernible from the SNP6.0 data, presumably because these cells
constituted a minor sub-population. Taken together, these data
suggest that these two sub-populations, with additional altera-
tions affecting the c-MYC gene, share an ancestral clone carrying
the focal 2.5 Mb ampliﬁcation. This model demonstrates additional
breaks in the proximity of c-MYC and ongoing evolution of this
locus as a result of cumulative radiation exposure.
c-MYC alterations in parental and irradiated MCF-10A breast
epithelial cells
The allelic location, magnitude and orientation of the alterations
affecting c-MYC in parental MCF-10A and cells from the 80 Gy
irradiated population were assessed by cytogenetic and meta-
phase ﬂuorescence in situ hybridisation (FISH) analysis. The region
of 8q gain present in parental MCF-10A cells was shown to be a
duplication and subsequent inversion to the end of chromosome
8p, which results in a derivative chromosome, der(8)t(8;8)(q22;
p23) (Figure 2a).
The large ~ 59 Mb gain ﬁrst identiﬁed in the 60 Gy population
and generated via the break in PVT1 is a tandem duplication of the
8q12–q24 region of the normal chromosome 8 giving rise to dup
(8)(q12–q24) (Figure 2b). FISH identiﬁed multiple copies of c-MYC
at both the expected 8q24 bands on the dup(8)(q12–q24)
chromosome (Figure 2b, inset), demonstrating that the ~ 59 Mb
duplication and the focal ampliﬁcation are on the same allele.
No evidence that the ~ 59 Mb duplication preceded the focal
ampliﬁcation was provided by metaphase FISH, and supports the
SNP array data in suggesting that the PVT1 break and ~ 59 Mb
duplication occurred subsequent and independent to the 2.5 Mb
focal ampliﬁcation.
Additional alterations that affected the c-MYC locus were
identiﬁed in minor sub-populations of cells that had received a
cumulative dose of 80 Gy (Supplementary Figure 2) and included a
translocation to an unidentiﬁed partner chromosome, a further
duplication of the der(8)t(8;8)(q22;p23) and a second tandem
duplication on the dup(8)(q12–q24).
c-MYC ampliﬁcation occurs at low cumulative radiation dose
c-MYC alterations were analysed by FISH in 100 interphase nuclei
from parental MCF-10A cells and irradiated cell populations. Three
predominant c-MYC genotypes were identiﬁed: three c-MYC and
two centromere 8 FISH signals (the parental MCF-10A genotype);
four c-MYC and two centromere signals and more than four c-MYC
and two centromere 8 signals (Figure 3a). It was not possible to
discern consistently the exact c-MYC copy number because of
signal clustering. Nevertheless, up to 12 discrete c-MYC hybridisa-
tion signals were apparent in some cells (Figure 3a).
Nuclei with four or more c-MYC hybridisation signals were not
detected in parental MCF-10A cells (Figure 3a). Nuclei with four
and more than four c-MYC FISH signals were identiﬁed ﬁrst in the
10 and 20 Gy populations, respectively, which suggests that copy
number gain of c-MYC occurred earlier in this irradiation series
than was apparent from SNP array analysis (Figure 3b).
The dominance of c-MYC-ampliﬁed cells in the 80 Gy population
suggests positive selection by sequential exposure to ionising
radiation. Consistent with this model, c-MYC-ampliﬁed cells were
signiﬁcantly more resistant to the cytotoxic effects of ionising
radiation compared with parental non-ampliﬁed cells (two-way
analysis of variance, P= 0.0027; Supplementary Figure 3), although
the phenotype was relatively modest (parental MCF-10A IC50
(half-maximal inhibitory concentration) = 3.1 Gy; c-MYC-ampliﬁed
80 Gy MCF-10A IC50 = 4.4 Gy).
Copy number gain of c-MYC results in increased c-MYC protein
expression
Concomitant with c-MYC ampliﬁcation, c-MYC protein expression
was higher in cells irradiated with a cumulative dose of 40 Gy
or greater compared with parental cells (one-way analysis of
variance, Po0.001) (Figures 3c and d). These data demonstrate
that low doses of ionising radiation induce copy number
alterations in human MCF-10A cells, and that c-MYC is susceptible
to multiple structurally diverse alterations, including high-level
ampliﬁcation, which results in increased expression of c-MYC
protein.
c-MYC alterations in primary HuMECs
To exclude the possibility that radiation-induced c-MYC copy
number gain was speciﬁc to immortalised cells, we next treated
low passage human mammary epithelial cells (HuMECs) with
ionising radiation and determined c-MYC copy number using FISH.
Cells were treated with an initial dose of 2 Gy and subsequently
treated with an additional dose of either 1 or 2 Gy, giving total
cumulative doses of 2, 3 and 4 Gy. Using FISH probes for c-MYC,
centromere 8 and IGH, we found evidence of polyploidy in all cell
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Figure 2. Alterations that affect c-MYC in MCF-10A cells. Partial
karyotype analyses of chromosomes 8 and FISH analysis for c-MYC
(red probe) and chromosome 8 centromere (green probe) on
4′,6-diamidino-2-phenylindole (DAPI) counterstained metaphase
nuclei in parental MCF-10A (a) and 80 Gy cumulative dose cells
(b). Chromosome arms are labelled on the ideograms adjacent to
the karyotype images. The 46 Mb region of chromosome arm 8q
gain present in parental MCF-10A cells is due to a duplication of
8qter-q22 and subsequent translocation to the end of the short arm
resulting in a derivative chromosome 8: der(8)t(8;8)(q22;p23). The
der(8)t(8;8)(q22;p23) is identiﬁed in both the parental and 80 Gy
MCF-10A cell populations. The 80 Gy population has a second
abnormal chromosome 8, which comprises a tandem duplication of
the 8q12–q24 region to the q-telomere of the constitutively normal
chromosome 8: dup(8)(q12–q24). FISH analysis conﬁrmed that
c-MYC is present in both the constitutive 46Mb region of gain on
der(8)t(8;8)(q22;p23) and the duplicated region on dup(8)(q12–q24)
identiﬁed in the 80 Gγ population. The magniﬁed view of the
acquired dup(8)(q12–q24) chromosome in the 80 Gγ population
(inset in b) shows that multiple copies of c-MYC are present at both
expected 8q24 chromosome positions.
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Figure 3. Genotypic and phenotypic alterations of c-MYC in irradiated huMECs and MCF-10A cells. c-MYC interphase FISH copy number
analysis of parental and irradiated MCF-10A populations. Three main cell populations were identiﬁed by FISH: cells with two copies of
chromosome 8 centromere (green probe) and three copies of c-MYC (red probe), cells with two copies of chromosome 8 and four copies of
c-MYC and cells with two copies of chromosome 8 and over four copies of c-MYC (a). The proportion of 100 scored nuclei with these three
c-MYC genotypes was combined and determined for each population. The proportion of nuclei with ⩾ 4 copies of c-MYC and therefore any cell
population with a c-MYC copy number gain was determined (b). Aliquots of 10 μg of protein extracted from parental and irradiated MCF-10A
cell populations were electrophoresed on polyacrylamide gels and analysed for c-MYC and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) expression by western transfer analysis as described in the Materials and methods (c). c-MYC expression was quantiﬁed for each cell
population by densitometric analysis of western blots from three independent protein samples (d). c-MYC expression is expressed as a
percentage of c-MYC expression in parental MCF-10A, which is set at 100% expression. Expression of c-MYC was signiﬁcantly higher in the
60 Gy population than parental MCF-10A (Turkey's test; Po0.05). c-MYC interphase FISH copy number analysis of parental and irradiated
HuMECs (e). Four main cell populations were identiﬁed by FISH: diploid cells (two copies of chromosome 8 centromere (aqua probe), two
copies of IGH (green probe) and two copies of c-MYC (red probe)); triploid cells (three copies of each locus); tetraploid cells (four copies of each
locus); cells with ampliﬁcation of c-MYC. At least 70 interphase cells were counted at each radiation dose (mock-treated, 2, 3 and 4 Gy) and
example images are shown for diploid, tetraploid and c-MYC-ampliﬁed cells.
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populations, including mock-treated control HuMECs. Interphase
FISH provided no evidence for speciﬁc c-MYC ampliﬁcation in
mock-treated HuMECs (Figure 3e). However, there was radiation
dose-dependent c-MYC ampliﬁcation in radiation-treated HuMECs
(Figure 3e). For example, in the 4 Gy population over 30% of the
scored cells (n= 73) had copy number gains of c-MYC relative to
the control loci (centromere 8 and IGH). Furthermore, we found
examples of diploid cells with at least seven distinct signals for
c-MYC and other cells, with clear clustering of c-MYC signals
(Figure 3e) indicative of focal ampliﬁcation and consistent with the
observations seen in MCF-10A.
c-MYC alterations in radiogenic breast cancer after Hodgkin
lymphoma
We investigated c-MYC copy number alterations and protein
expression in breast cancer following radiotherapy for Hodgkin
lymphoma (‘radiogenic breast cancer (RAD)’, n= 18; Supple-
mentary Table 4) and age-matched cases for which there was
no evidence of radiation exposure aetiology (‘sporadic breast
cancer (SPO)’, n= 33; Supplementary Table 5).
c-MYC copy number was assessed by FISH and was successful
for 20 of 33 (61%) sporadic breast cancer samples and 9 of 18
(50%) radiogenic breast cancer samples. c-MYC copy number was
higher in radiogenic compared with sporadic breast cancer
(Mann–Whitney U-test, P= 0.027; Figure 4a; Supplementary
Tables 6 and 7). Furthermore, 4 of 9 (44%) radiogenic breast
cancer cases had at least 10% of nuclei with 6 or more c-MYC
signals, compared with only 1 of 20 (5%) sporadic breast cancer
cases (Fisher's exact test, P= 0.022; Figure 4b).
Mechanisms and magnitude of c-MYC copy number gains in
radiogenic breast cancer
The pattern of centromere 8 and c-MYC hybridisation was studied
in each sample to investigate the mechanisms that underlie the
increase in c-MYC copy number. Although the majority of nuclei in
all the samples were diploid for chromosome 8, most samples
also had nuclei with more than two copies of centromere 8
(Supplementary Table 6). In some cases (e.g. SPO11 and SPO17),
there were nuclei with over six centromere 8 signals. Likewise, the
majority of samples had nuclei with apparent monosomy 8. These
data demonstrate a high level of both intra- and intertumour
heterogeneity with respect to chromosome 8 copy number status.
We determined the ratio between mean c-MYC and chromosome
8 signals to identify cases with speciﬁc c-MYC locus ampliﬁcation.
There was a higher c-MYC to centromere 8 ratio in radiogenic
breast cancer compared with sporadic breast cancer (Mann–
Whitney U-test, P= 0.016) (Figure 4c). Furthermore, more radio-
genic breast cancers (7 of 9, 77%) than sporadic breast cancers
(4 of 20, 20%) had a c-MYC to centromere 8 ratio 41.10 (Fisher's
exact test, P= 0.010; Figure 4d), indicating that locus-speciﬁc
c-MYC copy number gain is more common in radiogenic breast
cancer.
Two sporadic (e.g. SPO2, SPO28) and two radiogenic cases (e.g.
RAD9, RAD10) had high c-MYC to centromere 8 ratios (41.25) with
evidence of high-level c-MYC locus ampliﬁcation in the majority of
nuclei (Supplementary Tables 6 and 7). Dual hybridisation analysis
of these four c-MYC-ampliﬁed cases demonstrated that the
magnitude of c-MYC copy number gain was higher in the
radiogenic breast cancers compared with the sporadic cancers
Figure 4. FISH analysis of c-MYC copy number and chromosome 8 copy number in sporadic and radiogenic breast cancers. c-MYC copy
number was assessed in tumour cells from radiogenic cancers (n= 9) and from sporadic cancers (n= 20). c-MYC copy number was higher in
the radiogenic cancers (Mann–Whitney U-test; P= 0.027) (a). The wider horizontal bars represent the median c-MYC copy number and the
narrower horizontal bars represent the 10th and 90th percentiles of the data. The percentage of samples in which at least 10% of the nuclei
contained ⩾ 3, 4, 5 and 6 copies of c-MYC was compared (b) and was signiﬁcantly higher in the radiogenic cohort than in the sporadic cohort
for ⩾ 6 copies of c-MYC (Fisher's exact test; P= 0.022 (*)). The ratio between c-MYC and chromosome 8 centromere copy number was higher in
the radiogenic cohort than in the sporadic cohort (Mann–Whitney U-test; P= 0.016) (c). The percentage of samples in each cohort, which had
a c-MYC to chromosome 8 centromere ratio ⩽ 1.10 (no or little evidence of c-MYC ampliﬁcation) or 41.10 (evidence of c-MYC ampliﬁcation)
was also compared (d) (Fisher's exact test; P= 0.010).
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(Figure 5). Speciﬁcally, for SPO2 and SPO28, the majority of nuclei
with c-MYC ampliﬁcation had ﬁve and three c-MYC signals,
respectively, and included cells with up to seven and four c-MYC
signals, respectively (Figure 5b and Supplementary Table 6). For
RAD9 and RAD10, the majority of nuclei with c-MYC ampliﬁcation
had 5 and 9 c-MYC FISH signals, respectively, and included cells
with up to 13 and 14 c-MYC signals, respectively (Figure 5b and
Supplementary Table 6).
Taken together, these data indicate that c-MYC copy number
gain is more common in radiogenic breast cancer than in sporadic
disease, and that a greater proportion of radiogenic samples have
c-MYC copy number gains that affect speciﬁcally the c-MYC locus.
c-MYC expression in radiogenic breast cancer and correlation with
c-MYC copy number
We determined c-MYC protein expression in radiogenic and
sporadic breast cancers by immunohistochemistry and derivation
of a histoscore (Supplementary Figure 4). There was a trend
towards higher expression of c-MYC in the radiogenic breast
cancer compared with sporadic breast cancer (Figure 6a;
Mann–Whitney U-test, P= 0.119). Tumours in which c-MYC
immunoreactivity was detected in o10% of cells were considered
to be negative for expression (8 radiogenic (44%) and 16 sporadic
breast cancer cases (48%)). An analysis of all cases suggested
that exposure to ionising radiation was not associated with
SPO28
RAD9
RAD10
SPO2
c-MYC
CEP8
Figure 5. Dual-stain FISH analysis of samples that had a c-MYC to chromosome 8 centromere ratio 41.25. Representative FISH images of
samples SPO2 (ratio= 1.90), SPO28 (ratio= 1.28), RAD9 (ratio= 2.02) and RAD 10 (ratio= 2.50) for combined c-MYC (red) and chromosome 8
centromere (green) hybridisation (a). The results show that c-MYC-ampliﬁed cell populations from the radiogenic cohort have a higher degree
of ampliﬁcation compared with ampliﬁed cell populations from the sporadic cohort. The heterogeneity of c-MYC and chromosome 8
centromere copy number status is shown in the histograms to the right of the images for each sample (b).
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c-MYC-positivity (χ2 = 0.076: P= 0.782). However, comparison of
protein expression in c-MYC-positive tumours demonstrated
that the expression was signiﬁcantly higher in the radiogenic
breast cancer compared with sporadic breast cancer (Figure 6b;
Mann–Whitney U-test: Po0.001).
Samples were divided into three groups on the basis of c-MYC
protein expression: no or low c-MYC expression (histoscore: 0–50),
moderate expression (histoscore: 51–100) and high expression
(histoscore: 4100). The proportion of samples with no or low,
moderate or high c-MYC expression were different between the
radiogenic and sporadic cases, with high c-MYC expression
signiﬁcantly more common in the radiogenic series (Figure 6c;
χ2 = 8.041; P= 0.018).
We investigated if there was a correlation between c-MYC gene
copy number and protein expression and if there was a trend
towards higher c-MYC expression in samples with a mean c-MYC
copy number ⩾ 3 (n= 7) compared with samples with a c-MYC
copy number o3 (n= 22) (Mann–Whitney U-test, P= 0.115;
Figure 6d), although there was inconsistency between c-MYC
copy number and c-MYC protein expression in several cases
(Supplementary Table 8). In summary, these data demonstrate
that c-MYC expression is higher in radiogenic breast cancer
compared with sporadic disease. In some tumours, high c-MYC
copy number is reﬂected in high c-MYC protein expression but in
others the additional copies of c-MYC do not result in high levels
of protein expression.
DISCUSSION
We identiﬁed ionising radiation-induced genetic alterations
affecting c-MYC in immortalised non-transformed breast epithelial
cells that include high-level focal ampliﬁcation, duplication and
translocation. A particular strength of our study is that c-MYC
ampliﬁcation was generated directly by ionising radiation in a
controlled experimental system. Previous studies have suggested
that c-MYC ampliﬁcation is a late-stage event in radiation-induced
transformation.20,21 However, detailed single-cell analysis in this
study has identiﬁed several structurally diverse alterations of
c-MYC after relatively low radiation doses of 10–20 Gy. We also
identiﬁed high-level c-MYC ampliﬁcation in primary mammary
epithelial cells following radiation doses between 2 and 4 Gy.
High-level c-MYC ampliﬁcation was more common in human
breast cancer, which developed after radiotherapy compared with
breast cancer without antecedent radiation exposure, providing
additional evidence that ionising radiation speciﬁcally induces
c-MYC ampliﬁcation and implicates radiotherapy as one cause of
8q alterations in radiogenic breast cancer. In support of this
supposition, recurrent ampliﬁcation of the c-MYC locus has been
reported in breast cancers that developed in atomic bomb
survivors.14
Detailed single-cell analysis also revealed considerable intra-
and intertumour heterogeneity with respect to c-MYC copy
number in human radiogenic breast cancer, suggesting contin-
uous evolution at this locus during disease development
and progression. Taken together, these observations suggest
RAD13
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Figure 6. c-MYC protein expression in radiogenic and sporadic breast cancers. Formalin-ﬁxed, parafﬁn-embedded tissue from sporadic (n= 33)
and radiogenic (n= 18) breast cancers were sectioned and analysed by immunohistochemistry with a speciﬁc c-MYC antibody as described in
the Materials and methods. The level of c-MYC expression was quantiﬁed by derivation of a histoscore. c-MYC expression in the sporadic and
radiogenic breast cancers was compared for all cases (a) and was higher in radiogenic cases in which more than 10% of the nuclei had
detectable c-MYC expression (Mann–Whitney U-test: Po0.001) (b). The proportion of sporadic and radiogenic breast cancer that had c-MYC
expression histoscores of 0–50, 51–100 and 4100 were compared (χ2: P= 0.018) (c). The number of samples in each group in panel (c) is
identiﬁed above each bar of the histogram. c-MYC expression is shown in tumours known to have a c-MYC copy number of o3 (n= 22) or ⩾ 3
(n= 7) (d). The wider horizontal bars represent the median c-MYC copy numbers and the narrower horizontal bars represent the 10th and 90th
percentiles of the data (a, b and d). Representative IHC images of samples with no c-MYC expression (RAD13: histoscore= 0), moderate
expression (RAD9: histoscore= 70.4) and high expression (RAD6; histoscore= 158.8) are shown in (e).
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progressive accumulation of alterations and provide strong
evidence that this locus is particularly sensitive to radiation-
induced alteration.
There is evidence suggesting that c-MYC is intrinsically unstable
in human breast cells. Kadota et al.22 identiﬁed a spontaneous
single-copy c-MYC gain in MCF-10A cells, but there was no
evidence of high-level ampliﬁcation. The breakpoints of the single-
copy gain do not match those reported in our study, which are
associated with high-level focal c-MYC ampliﬁcation. Diverse
breakpoints suggest several putative fragile sites at the c-MYC
locus. Common fragile sites with a particular propensity to
undergo breakage during replication stress exist in the human
genome.23 Two such common fragile sites, FRA8C and FRA8D,
ﬂank c-MYC and breakage at these sites have been identiﬁed in
cervical cancer and Burkitt lymphoma.24 Furthermore, radiation-
induced genotoxic stress, which in turn induces replication stress,
has been shown to induce breaks at fragile sites in the rat
genome.25
Our study has clearly demonstrated an association between
antecedent radiation exposure and elevated expression of c-MYC
in breast cancer. A clear link between radiation-induced c-MYC
ampliﬁcation and elevated c-MYC protein expression was
demonstrated in vitro using cultured human breast cells. This
association was also seen in breast cancer tissue, although the
correlation was relatively weak. Reports of a weak correlation
between c-MYC copy number and protein expression in cancer are
common, and have been described in breast, pancreatic, bladder
and colon disease.26–29 Expression of c-MYC is regulated by
multiple pathways and is known to be highly regulated by cell
cycle state (quiescence/proliferation), irrespective of whether
there is gene ampliﬁcation.30,31 As such, cases in which c-MYC
protein expression does not increase with gene copy number
could indicate a low proliferative index or mechanisms disrupting
transcription/protein stability.
Furthermore, a mechanism has been identiﬁed that could be
responsible for increased c-MYC expression in radiogenic breast
cancer without the requirement of c-MYC ampliﬁcation. Best
et al.32 identiﬁed a risk haplotype for radiogenic breast cancer at
the PRDM1 (BLIMP1) locus on 6q. PRDM1 is a negative transcrip-
tional regulator of c-MYC and the risk haplotype is associated with
reduced PRDM1 expression, attenuated upregulation of PRDM1
and increased expression of c-MYC in response to ionising
radiation. The ﬁndings of our study and the identiﬁcation of the
PRDM1 risk haplotype strongly suggest an important role for
c-MYC overexpression in radiogenic breast cancer development,
and we can speculate that radiation-induced c-MYC ampliﬁcation
may be an important driver of c-MYC dysregulation in some, but
not all, cases of radiogenic breast cancer.
c-MYC is a well-established proto-oncogene, which when
overexpressed drives cell proliferation,30,33,34 blocks cell
differentiation,34,35 promotes angiogenesis36 and genetic
instability.37,38 Overexpression of c-MYC has been associated with
radiation resistance, which could confer a survival advantage
during a fractioned therapeutic dosing regimen and could be an
important phenotype required for cell transformation.39–42 The
application of targeted therapy against cells with dysregulated
c-MYC expression43 could therefore prove efﬁcacious in the
treatment of radiogenic breast cancer and might have value to
prophylactically inhibit the outgrowth of c-MYC deregulated cells
following radiation exposure.
In conclusion, this study demonstrates that ionising radiation
directly induces genetic alterations affecting c-MYC, including
translocation and high-level focal ampliﬁcation, and identiﬁes
c-MYC as a radiosensitive locus. Importantly, c-MYC protein
expression was signiﬁcantly elevated in radiation-exposed breast
cells, emphasising the importance of this critical transcription
factor in radiogenic breast cancer. Our ﬁndings provide insight
into the aetiology of radiogenic breast cancer and may have
relevance to other cancers with a radiation exposure aetiology.
MATERIALS AND METHODS
Primary mammary epithelial cells (HuMECs) and MCF-10A cells
HuMECs were obtained from Gibco (Life Technologies, Paisley, UK) and
maintained in HuMEC Ready Medium (Life Technologies). MCF-10A cells
were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and cultured in the medium as described
previously44 supplemented with 10 nM 17-β oestradiol. MCF-10A cells are
a non-transformed breast epithelial cell line derived from non-malignant
human ﬁbroblastic mammary tissue immortalised by extended cultivation
in low calcium concentrations.45 The karyotype of MCF-10A is near diploid
with a t(3;9)(p13;p22) and an unbalanced translocation between part of
chromosome 5 to the short arm of the derivative chromosome 9, which
results in a deletion of CDKN2A/CDKN2B, which is thought be responsible
for the immortalisation of this cell line. MCF-10A carries a duplication of
part of the long arm of chromosome 8 (8q), trisomy for chromosome 20,
trisomy for the long arm of chromosome 1 (1q) and an additional copy of
chr1: 198 136 766-qter (19).
Irradiation of MCF-10A and HuMECs
MCF-10A cells were exposed to 5 and 10 Gy fractionated doses of
X-irradiation (2.5 Gy/min) to a cumulative dose of 80Gy using a D3300
X-ray system (Gulmay Medical Ltd, Chertsey, UK). To test the stability of
MCF-10A cells in continuous culture, unirradiated cells were cultured under
the same conditions and for the same length of time as irradiated cells
(termed ‘untreated MCF-10A’). Clonal populations of cells that had received a
cumulative dose of 80 Gy were generated by plating cells at a density of 1 cell
per well in a 96-well plate. HuMECs were exposed to an initial 2 Gy dose of
X-irradiation (2.5 Gy/min) followed by an additional dose of either 1 or 2 Gy.
Clonogenic assay
Parental MCF-10A cells and cells from the 80 Gy population were plated at
a density of 200 cells per well in a 6-well plate and irradiated (0–15 Gy) 24 h
later. Cell colonies were allowed to grow for 7 days before ﬁxation with 3:1
methanol:acetic acid and staining with crystal violet. Colonies were
counted by two independent researchers from duplicate wells in three
independent experiments.
Genome-wide SNP array analysis
Genomic DNA was extracted with a QIAmp DNA Mini Kit (Qiagen, Limburg,
The Netherlands) and analysed by Affymetrix Human SNP6.0 or Cytoscan
Array (Affymetrix). Analysis of untreated MCF-10A cells identiﬁed acquired
trisomy 7, 8, 11, 13 and 19, in addition to the trisomy 20 identiﬁed
previously in parental MCF-10A cells.20 There was no evidence of any other
acquired copy number alterations in the genome of untreated MCF-10A
cells, other than those identiﬁed in parental MCF-10A cells.
G-band karyotyping of MCF-10A cells
Metaphase chromosome spreads were prepared by incubating proliferat-
ing cells with 100 ng/ml colcemid for 4 h followed by resuspension in
75mM KCl for 7 min. Cells were ﬁxed by resuspension in 3:1 methanol:
acetic acid before karyotyping and FISH analysis. Slide-ﬁxed cells were
incubated overnight at 60 °C and G-banded by soaking in the trypsin
solution (1.9 mg/ml trypsin, 74 mM NaCl, 0.469mg/ml NaH2PO4 and
0.937mg/ml Na2HPO4) for 10 s and in the staining solution (8 ml Giemsa
stain, 0.5 ml Leishman stain and 40ml Gurr buffer (0.469mg/ml NaH2PO4
and 0.937mg/ml Na2HPO4)) for 3 min. Twenty metaphase chromosome
spreads were analysed for each population and the karyotypes recorded.
FISH analysis of HuMECs and MCF-10A cells
c-MYC and centromere 8 copy number status of MCF-10A cell populations
was determined by dual hybridisation with a Vysis LSI SpectrumOrange
c-MYC Probe (Abbott Molecular, Maidenhead, UK; cat. no.: 05J545-011) and
a CEP8 SpectrumGreen Probe (Abbott Molecular; cat. no.: 06J37-018) as
recommended by the suppliers. c-MYC (orange), centromere 8 (aqua) and
IGH (green) copy number status of HuMECs was determined using the
Abbott IGH/MYC/CEP8 Tri-colour Dual Fusion Translocation Probe (Abbott
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Molecular). Slides were heated to 72 °C for 5 min and then incubated for
24 h at 37 °C in a humidiﬁed hybridisation chamber (HYBrite; Abbott
Molecular). After hybridisation, slides were counterstained with 4′,6-
diamidino-2-phenylindole (Vector Laboratories, Peterborough, UK). FISH
was scored with an Olympus BX-61 ﬂuorescence microscope (Olympus,
Southend-on-Sea, UK) with a x100 oil objective. Images were analysed
using the CytoVision 7.2 SPOT counting system (Leica Microsystems,
Gateshead, UK). A minimum of 100 (for MCF-10A) or 70 (for HuMECs) nuclei
were scored per test by two independent analysts.
Western transfer analysis
Proliferating MCF-10A cells were lysed in 50mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1% (w/v) NP-40, 0.25% (w/v) sodium deoxycholate,
1 μg/ml pepstatin, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 2 mM sodium
orthovanadate, 2 mM sodium ﬂuoride and 2mM phenylmethylsulphonyl
ﬂuoride. Aliquots of 10μg protein were separated by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis, transferred to nitrocellulose
and incubated with antibodies speciﬁc to c-MYC (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA; no. 262) and glyceraldehyde 3-phosphate
dehydrogenase (Santa Cruz Biotechnology; FL-335). The signal was
detected with SuperSignal (Thermo Scientiﬁc, Rockford, IL, USA) and
exposure to X-ray ﬁlm (Fujiﬁlm, Tokyo, Japan) and quantiﬁed using Lab
Works 4.0 software (Ultra-Violet Products, Upland, CA, USA). Variations in
the amount of protein loaded for each sample was normalised using
glyceraldehyde 3-phosphate dehydrogenase. Protein in irradiated cells is
expressed relative to parental MCF-10A from three independent samples.
Breast cancer cases
This study was approved by the United Kingdom National Research Ethics
Committee (nos 06/Q1108/91 and 07/Q0904/25). Breast cancer tissue was
obtained from 18 women who had received radiotherapy to the chest for
Hodgkin lymphoma (termed ‘radiogenic breast cancer’ samples). An age-
and tumour-type matched series of breast cancer cases was selected from
patients with no history of prior cancer or therapeutic radiation exposure
(termed ‘sporadic breast cancer’ samples).
c-MYC and centromere 8 FISH of breast cancer tissue samples
Formalin-ﬁxed, parafﬁn-embedded breast tissue was dewaxed, rehydrated
and digested by incubation in 0.005% proteinase K 0.05 M Tris-HCl (pH 7.5),
0.01 M EDTA and 0.01 M NaCl for 30min at 37 °C and then resuspended in
40% (v/v) methanol in phosphate-buffered saline. Samples were disag-
gregated and cytospin slides of isolated nuclei were generated. Samples
were incubated in 100 μg/ml RNAse, 0.015 M Na3C6H5O7, 0.15 M NaCl for
30min at 37 °C in a humidiﬁed hybridisation chamber and then
dehydrated in ethanol. Nuclei were digested in 1mg/ml pepsin, 0.01 M
HCl for 30min at 37 °C in a humidiﬁed hybridisation chamber and then
washed, dehydrated and air-dried. The Vysis LSI SpectrumOrange c-MYC
Probe (Abbott Molecular) and CEP8 SpectrumGreen Probe (Abbott
Molecular) were each hybridised separately to isolated nuclei because
dual hybridisation did not produce strong enough signal for several
samples. FISH protocols were the same as described above except that the
samples were incubated at 85 °C for 30min and then hybridised for 48 h at
37 °C. FISH was successful for 20 of 33 (61%) sporadic breast cancer
samples and 9 of 18 (50%) radiogenic breast cancer samples and
100 nuclei were scored for each probe by two independent analysts.
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded breast tissue was dewaxed, rehydrated
and antigen retrieval was achieved by incubation in 10mM Tris, 1 mM EDTA
buffer (pH 9) for 30 s at 125 °C in a Menapath Antigen Access Retrieval Unit
(A Menarini Diagnostics, Wokingham, UK). The tissue was incubated in 3%
(v/v) hydrogen peroxide solution for 10min at room temperature and then
washed in 0.02 M Tris-HCl, 0.14 M NaCl and 0.1% (v/v) Tween-20. It was also
incubated at room temperature for 60min with an antibody speciﬁc for
c-MYC (Epitomics, Burlingame, CA, USA; cat. no.:1472-1) in Tris-buffered
saline (pH 7.6) and then with Menapath HRP Polymer (A Menarini
Diagnostics) for 30min. Sections were visualised with 3,3′ diaminobezidine
and were counterstained with Gills II haematoxylin. c-MYC expression was
quantiﬁed by the analysis of 100 malignant epithelial cells in each of ﬁve
ﬁelds. The intensity of the immunoreaction was scored from 0 to 3
(Supplementary Figure 4) by two independent researchers. A histoscore
was calculated for each case from the sum of the scores for 500 cells.
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